1825. In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-resistant (MDR) Isolates, Over a Three-year Period (2013-15)
Session: Poster Abstract Session: Antibacterial Susceptibility Surveillance
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • 1825_FINAL.pdf (296.7 kB)
  • Background: Eravacycline (ERV) is a novel, fully synthetic fluorocycline antibiotic of the tetracycline class being developed for the treatment of serious infections, including those caused by MDR pathogens. The purpose of this study was to evaluate activity of ERV and comparators against global isolates of Enterobacteriaceae (ENT), A. baumannii (AB), and S. maltophilia (SM), including those resistant to carbapenems (CR) or 3rd/4thgeneration cephalosporins (ESC-R).

    Methods: Global clinical isolates were collected from 2013-15. MICs for ERV and comparators were determined by CLSI broth microdilution. Susceptibility was determined with CLSI 2015 breakpoints where available. MDR was defined as resistant to at least 1 agent in 3 or more antimicrobial categories. ESC-R was defined as resistant to ceftriaxone, cefotaxime, ceftazidime, or cefepime. CR was defined as resistant to imipenem or meropenem.

    Results: The ERV MIC50/90 for all ENT (n=6878) was 0.25/2 mg/L, and for MDR-ENT (N=1076) was 0.5/2 mg/L. The ERV MIC50/90s for ESC-R-ENT and CR-ENT were 0.5/2 and 1/2 mg/L, respectively. ERV MIC90for the organisms did not vary more than one dilution over the 3-year time range.

    Organism (N)

    ERV

    TGC

    CST

    MIC50/90

    MIC range

    MIC50/90

    MIC range

    MIC50/90

    MIC range

    E. coli(986)

    ESC-R (180)

    0.12/0.25

    0.25/0.5

    0.06-2

    0.06-1

    0.25/0.5

    0.25/0.5

    0.12-4

    0.12-4

    0.5/1

    0.5/1

    0.25-4

    0.25-2

    K. pneumoniae (958)

    ESC-R (196)

    CR (61)

    0.25/1

    0.5/1

    0.5/2

    0.12-8

    0.12-4

    0.25-2

    1/2

    1/2

    1/2

    0.12-16

    0.12-8

    0.5-4

    0.5/1

    0.5/1

    0.5/4

    <0.12-40.25->4

    0.25->4

    S. marcescens (599)

    ESC-R (59)

    CR (11)

    1/2

    2/4

    1/2

    0.25-8

    0.5-4

    1-4

    2/2

    2/4

    2/4

    0.25-16

    0.5-4

    1-4

    >4/>4

    >4/>4

    >4/>4

    0.5->4

    0.5->4

    >1->4

    A. baumannii(1094)

    CR (705)

    0.5/2

    1/2

    0.03-8

    0.06-8

    2/4

    2/4

    0.06->16

    0.25->16

    1/2

    1/2

    0.25->32

    0.25->32

    S. maltophilia (619)

    1/2

    0.03-16

    1/4

    0.06-16

    1/8

    <0.12->32

    CST - colistin; MIC50/90- minimum inhibitory concentration (mg/L) required to inhibit growth of 50/90% of isolates

    Conclusion: ERV shows activity against ENT, AB, and SM, including resistant phenotypes. Potency of ERV against ENT was up to 2-fold greater than TGC, including MDR and ESC-R, and up to 4-fold greater for CR. Potency of ERV against AB and SM was 2-fold greater than TGC.

    Matteo Bassetti, MD, PhD1, Ralph Corey, MD2, Yohei Doi, MD, PhD3, Ian Morrissey, PhD4, Trudy Grossman, PhD5, Melanie Olesky, PhD6, Patrick Scoble, PharmD7 and Joyce Sutcliffe, PhD6, (1)Santa Maria Misericordia Hospital, Udine, Italy, (2)Duke University Medical Center, Durham, NC, (3)Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, (4)IHMA Europe Sàrl, Epalinges, Switzerland, (5)Tetraphase Pharmaceuticals, Watertown, MA, (6)Tetraphase Pharmaceuticals, Inc., Watertown, MA, (7)Former Employee Tetraphase Pharmaceuticals, Watertown, MA

    Disclosures:

    M. Bassetti, None

    R. Corey, None

    Y. Doi, None

    I. Morrissey, IHMA: Employee , Salary

    T. Grossman, Tetraphase Pharmaceuticals: Employee , Salary

    M. Olesky, Tetraphase Pharmaceuticals: Employee , Salary

    P. Scoble, Tetraphase Pharmaceuticals: Employee , Salary

    J. Sutcliffe, Tetraphase Pharmaceuticals: Employee , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.